TJ0113
Asset
Selective mitophagy activator
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Autophagy
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Parkinson's disease
Phase 2, phecdamed.com, 7 Oct 2026
Sarcopenia
Phase 2, Recruiting, NCT07620938, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Aging relevance2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.